Loading…

Estimating the Value of a Generic Quality-of-Life Measure

In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are m...

Full description

Saved in:
Bibliographic Details
Published in:Medical care 1995-04, Vol.33 (4), p.AS195-AS202
Main Authors: Mauskopf, Josephine A., Austin, Randall, Dix, Lynn P., Berzon, Richard A.
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page AS202
container_issue 4
container_start_page AS195
container_title Medical care
container_volume 33
creator Mauskopf, Josephine A.
Austin, Randall
Dix, Lynn P.
Berzon, Richard A.
description In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.
format article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_77223874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>3766626</jstor_id><sourcerecordid>3766626</sourcerecordid><originalsourceid>FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3</originalsourceid><addsrcrecordid>eNo9j81KxDAYRbNQxnH0DRSychdI8_dNljKMo1ARQd2WtPmqKf0Zm3Qxb29hiqu7OIcL54KsOReaAQd7Ra5jbDjPQGqxIisAIZWCNbH7mELnUui_afpB-uXaCelQU0cP2OMYKvo-uTakExtqloca6Su6OI14Qy5r10a8XXZDPp_2H7tnlr8dXnaPOWuEsIlliAjCCqid0cqWQlqdKe69BsMzI8tSafTSiS2Cs145CV5zpTxUVgks5YY8nH-P4_A7YUxFF2KFbet6HKZYzClCbkHN4v0iTmWHvjiOc9h4KpbWmd-deRPTMP5jCcYYYeQfdnNWoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77223874</pqid></control><display><type>article</type><title>Estimating the Value of a Generic Quality-of-Life Measure</title><source>JSTOR Archival Journals and Primary Sources Collection</source><creator>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</creator><creatorcontrib>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</creatorcontrib><description>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</description><identifier>ISSN: 0025-7079</identifier><identifier>PMID: 7723447</identifier><language>eng</language><publisher>United States: J. B. Lippincott Co</publisher><subject>Acyclovir - analogs &amp; derivatives ; Acyclovir - therapeutic use ; Antiviral Agents - therapeutic use ; Central nervous system viral diseases ; Choosing Questions ; Clinical trials ; Demography ; Diabetes ; Double-Blind Method ; Exanthema ; Female ; Herpes zoster ; Herpes Zoster - drug therapy ; Herpes Zoster - psychology ; Humans ; Male ; Middle Aged ; Nervous system diseases ; Outcome Assessment (Health Care) ; Pain ; Pain - psychology ; Prognosis ; Quality of Life ; Regression Analysis ; Sleep ; Symptoms ; Valine - analogs &amp; derivatives ; Valine - therapeutic use</subject><ispartof>Medical care, 1995-04, Vol.33 (4), p.AS195-AS202</ispartof><rights>Copyright 1995 J. B. Lippincott Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/3766626$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/3766626$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7723447$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mauskopf, Josephine A.</creatorcontrib><creatorcontrib>Austin, Randall</creatorcontrib><creatorcontrib>Dix, Lynn P.</creatorcontrib><creatorcontrib>Berzon, Richard A.</creatorcontrib><title>Estimating the Value of a Generic Quality-of-Life Measure</title><title>Medical care</title><addtitle>Med Care</addtitle><description>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</description><subject>Acyclovir - analogs &amp; derivatives</subject><subject>Acyclovir - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Central nervous system viral diseases</subject><subject>Choosing Questions</subject><subject>Clinical trials</subject><subject>Demography</subject><subject>Diabetes</subject><subject>Double-Blind Method</subject><subject>Exanthema</subject><subject>Female</subject><subject>Herpes zoster</subject><subject>Herpes Zoster - drug therapy</subject><subject>Herpes Zoster - psychology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous system diseases</subject><subject>Outcome Assessment (Health Care)</subject><subject>Pain</subject><subject>Pain - psychology</subject><subject>Prognosis</subject><subject>Quality of Life</subject><subject>Regression Analysis</subject><subject>Sleep</subject><subject>Symptoms</subject><subject>Valine - analogs &amp; derivatives</subject><subject>Valine - therapeutic use</subject><issn>0025-7079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNo9j81KxDAYRbNQxnH0DRSychdI8_dNljKMo1ARQd2WtPmqKf0Zm3Qxb29hiqu7OIcL54KsOReaAQd7Ra5jbDjPQGqxIisAIZWCNbH7mELnUui_afpB-uXaCelQU0cP2OMYKvo-uTakExtqloca6Su6OI14Qy5r10a8XXZDPp_2H7tnlr8dXnaPOWuEsIlliAjCCqid0cqWQlqdKe69BsMzI8tSafTSiS2Cs145CV5zpTxUVgks5YY8nH-P4_A7YUxFF2KFbet6HKZYzClCbkHN4v0iTmWHvjiOc9h4KpbWmd-deRPTMP5jCcYYYeQfdnNWoA</recordid><startdate>19950401</startdate><enddate>19950401</enddate><creator>Mauskopf, Josephine A.</creator><creator>Austin, Randall</creator><creator>Dix, Lynn P.</creator><creator>Berzon, Richard A.</creator><general>J. B. Lippincott Co</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19950401</creationdate><title>Estimating the Value of a Generic Quality-of-Life Measure</title><author>Mauskopf, Josephine A. ; Austin, Randall ; Dix, Lynn P. ; Berzon, Richard A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Acyclovir - analogs &amp; derivatives</topic><topic>Acyclovir - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Central nervous system viral diseases</topic><topic>Choosing Questions</topic><topic>Clinical trials</topic><topic>Demography</topic><topic>Diabetes</topic><topic>Double-Blind Method</topic><topic>Exanthema</topic><topic>Female</topic><topic>Herpes zoster</topic><topic>Herpes Zoster - drug therapy</topic><topic>Herpes Zoster - psychology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous system diseases</topic><topic>Outcome Assessment (Health Care)</topic><topic>Pain</topic><topic>Pain - psychology</topic><topic>Prognosis</topic><topic>Quality of Life</topic><topic>Regression Analysis</topic><topic>Sleep</topic><topic>Symptoms</topic><topic>Valine - analogs &amp; derivatives</topic><topic>Valine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mauskopf, Josephine A.</creatorcontrib><creatorcontrib>Austin, Randall</creatorcontrib><creatorcontrib>Dix, Lynn P.</creatorcontrib><creatorcontrib>Berzon, Richard A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medical care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mauskopf, Josephine A.</au><au>Austin, Randall</au><au>Dix, Lynn P.</au><au>Berzon, Richard A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimating the Value of a Generic Quality-of-Life Measure</atitle><jtitle>Medical care</jtitle><addtitle>Med Care</addtitle><date>1995-04-01</date><risdate>1995</risdate><volume>33</volume><issue>4</issue><spage>AS195</spage><epage>AS202</epage><pages>AS195-AS202</pages><issn>0025-7079</issn><abstract>In this paper, data from a clinical trial of a new antiviral agent for treating patients with zoster are used to answer the following question: Does the Nottingham Health Profile (NHP) add to the information obtained from the clinical measures? Three ways in which the NHP could add information are measured. First, Cox's regression analysis is used to determine whether health-related quality-of-life scores obtained at diagnosis give information about disease prognosis. Second, changes in mean NHP scores in different dimensions are computed after pain resolution to determine whether NHP scores provide more sensitive indicators of disease resolution. Third, linear regression is used to determine whether the impacts of disease on quality of life are measured adequately by the clinical parameters. These analyses show that use of the physical mobility and energy dimensions of the NHP increases understanding of disease prognosis; demonstrates the continuing impact of zoster on patients' sleep patterns and energy levels, disease symptoms not included as clinical measures, that persist after the cessation of zoster-associated pain; and gives a measure of the impact of zoster on the patient, which includes unmeasured and measured levels of severity.</abstract><cop>United States</cop><pub>J. B. Lippincott Co</pub><pmid>7723447</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0025-7079
ispartof Medical care, 1995-04, Vol.33 (4), p.AS195-AS202
issn 0025-7079
language eng
recordid cdi_proquest_miscellaneous_77223874
source JSTOR Archival Journals and Primary Sources Collection
subjects Acyclovir - analogs & derivatives
Acyclovir - therapeutic use
Antiviral Agents - therapeutic use
Central nervous system viral diseases
Choosing Questions
Clinical trials
Demography
Diabetes
Double-Blind Method
Exanthema
Female
Herpes zoster
Herpes Zoster - drug therapy
Herpes Zoster - psychology
Humans
Male
Middle Aged
Nervous system diseases
Outcome Assessment (Health Care)
Pain
Pain - psychology
Prognosis
Quality of Life
Regression Analysis
Sleep
Symptoms
Valine - analogs & derivatives
Valine - therapeutic use
title Estimating the Value of a Generic Quality-of-Life Measure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimating%20the%20Value%20of%20a%20Generic%20Quality-of-Life%20Measure&rft.jtitle=Medical%20care&rft.au=Mauskopf,%20Josephine%20A.&rft.date=1995-04-01&rft.volume=33&rft.issue=4&rft.spage=AS195&rft.epage=AS202&rft.pages=AS195-AS202&rft.issn=0025-7079&rft_id=info:doi/&rft_dat=%3Cjstor_proqu%3E3766626%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-j229t-1eee72927fa6549b2395140dd5760163bb45ed3a28e7a9d4a37d5044d7c942eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77223874&rft_id=info:pmid/7723447&rft_jstor_id=3766626&rfr_iscdi=true